标题
Axitinib: A Review in Advanced Renal Cell Carcinoma
作者
关键词
Sorafenib, Sunitinib, National Comprehensive Cancer Network, Temsirolimus, Metastatic Renal Cell Carcinoma
出版物
DRUGS
Volume 75, Issue 16, Pages 1903-1913
出版商
Springer Nature
发表日期
2015-10-20
DOI
10.1007/s40265-015-0483-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma
- (2015) B. I. Rini et al. ANNALS OF ONCOLOGY
- Effect of axitinib on the QT interval in healthy volunteers
- (2015) Ana Ruiz-Garcia et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma
- (2015) Bernard Escudier et al. Clinical Genitourinary Cancer
- 2615 Efficacy and tolerability of axitinib in metastatic renal cell carcinoma (mRCC): Comparison of Czech clinical registry and AXIS trial data
- (2015) B. Melichar et al. EUROPEAN JOURNAL OF CANCER
- 2509 Overall survival analysis from a randomised phase III trial of axitini vs sorafenib as first-line therapy in patients with metastatic renal cell carcinoma
- (2015) T.E. Hutson et al. EUROPEAN JOURNAL OF CANCER
- 2600 Axitinib in second and further line for metastatic renal cell carcinoma (RCC): Real world data from 2 teaching hospitals in Birmingham, UK
- (2015) C. Canipari et al. EUROPEAN JOURNAL OF CANCER
- Cost-effectiveness analysis of axitinib through a probabilistic decision model
- (2015) Panagiotis Petrou EXPERT OPINION ON PHARMACOTHERAPY
- Axitinib plasma pharmacokinetics and ethnic differences
- (2015) Ying Chen et al. INVESTIGATIONAL NEW DRUGS
- MP39-20 MOLECULAR MECHANISM UNDERLYING CYTOTOXIC ACTIVITY OF AXITINIB IN SUNITINIB-RESISTANT HUMAN RENAL CELL CARCINOMA ACHN CELLS
- (2015) Akira Miyazaki et al. JOURNAL OF UROLOGY
- The European Medicines Agency Approval of Axitinib (Inlyta) for the Treatment of Advanced Renal Cell Carcinoma After Failure of Prior Treatment With Sunitinib or a Cytokine: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
- (2015) K. Tzogani et al. ONCOLOGIST
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) B. Escudier et al. ANNALS OF ONCOLOGY
- Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma
- (2014) Masatoshi Eto et al. CANCER SCIENCE
- Population Pharmacokinetic-Pharmacodynamic Modelling of 24-h Diastolic Ambulatory Blood Pressure Changes Mediated by Axitinib in Patients with Metastatic Renal Cell Carcinoma
- (2014) Ying Chen et al. CLINICAL PHARMACOKINETICS
- Controversies in renal cell carcinoma: Treatment choice after progression on vascular endothelial growth factor-targeted therapy
- (2014) Emiliano Calvo et al. EUROPEAN JOURNAL OF CANCER
- Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib
- (2014) Hideaki Miyake et al. International Journal of Clinical Oncology
- Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
- (2014) Brian I. Rini et al. Targeted Oncology
- Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
- (2013) D Cella et al. BRITISH JOURNAL OF CANCER
- Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis
- (2013) Wei-Xiang Qi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Population pharmacokinetic analysis of axitinib in healthy volunteers
- (2013) May Garrett et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Treated With Axitinib
- (2013) Brian I. Rini et al. Clinical Genitourinary Cancer
- Clinical Pharmacology of Axitinib
- (2013) Ying Chen et al. CLINICAL PHARMACOKINETICS
- Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
- (2013) T. Ueda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2013) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
- (2013) Brian I. Rini et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Axitinib in advanced renal-cell carcinoma
- (2013) Nadia Yousaf et al. LANCET ONCOLOGY
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
- (2013) Thomas E Hutson et al. LANCET ONCOLOGY
- Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
- (2013) Brian I Rini et al. LANCET ONCOLOGY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Molecular Marker for Predicting Treatment Response in Advanced Renal Cell Carcinoma: Does the Promise Fulfill Clinical Need?
- (2013) Michael Garcia-Roig et al. Current Urology Reports
- Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action
- (2012) José Luís González Larriba et al. CANCER AND METASTASIS REVIEWS
- Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers
- (2012) Yazdi K. Pithavala et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
- (2011) B. I. Rini et al. CLINICAL CANCER RESEARCH
- Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma
- (2011) Yoshihiko Tomita et al. EUROPEAN JOURNAL OF CANCER
- Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics
- (2011) Meghan Brennan et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers
- (2011) Y. Chen et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
- (2011) Yutaka Fujiwara et al. INVESTIGATIONAL NEW DRUGS
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
- (2010) Yazdi K. Pithavala et al. INVESTIGATIONAL NEW DRUGS
- Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
- (2010) Michael A. Tortorici et al. INVESTIGATIONAL NEW DRUGS
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
- (2010) Michael L. Maitland et al. JNCI-Journal of the National Cancer Institute
- Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
- (2009) Y. K. Pithavala et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: A phase I study in Japanese patients
- (2009) Toru Mukohara et al. CANCER SCIENCE
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started